1. Scrip
  2. >>Business

BMS Speeds Expansion Into Neuroscience With $14bn Karuna Buy

Schizophrenia Drug Approval Expected In September

 
• By Mandy Jackson

Bristol Myers Squibb will double its neuroscience portfolio from one to two drugs after it pays $330 per share for Karuna and its lead asset KarXT, accelerating the big pharma’s diversification plans.

Abstract human brain. Artificial intelligence new technology. Science futuristic background
Bristol will go from a few Phase II-ready neuroscience programs to multiple late-stage trials • Source: Shutterstock

Bristol Myers Squibb Company is paying $14bn to rapidly ramp up its neuroscience portfolio through the acquisition of Karuna Therapeutics, Inc. and its M1/M4 receptor agonist KarXT (xanomeline-trospium), which is filed with the US Food and Drug Administration for the treatment of schizophrenia with a 26 September 2024 action date. The deal announced on 22 December gives BMS a product with blockbuster potential across multiple indications plus much-needed diversification of its portfolio.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business